America's Choice for CGM Supplies
Aptiva Medical, a prominent provider of continuous glucose monitoring (CGM) systems, has successfully acquired VeraMed Health, a move that significantly broadens its national patient base and enhances its operational capabilities. The announcement, made on October 7, 2025, marks a strategic step for Aptiva Medical in strengthening its leadership within the CGM distribution market.
The acquisition of VeraMed Health is expected to not only expand Aptiva’s referral and payer networks but also to accelerate its growth trajectory. This development positions Aptiva Medical as a more formidable player in the diabetes management sector, which is increasingly vital as the prevalence of diabetes continues to rise across various demographics.
Greenleaf Ventures, the private investment firm overseeing Aptiva Medical, has a strong history of scaling healthcare companies. Founded by Timothy Stocksdale and David Wallace, the firm has successfully built companies such as Access Diabetic Supply and Liberty Medical, the latter of which was acquired out of bankruptcy in 2014 and later sold to Cardinal Health. Their experience and track record in the healthcare field lend credibility to this acquisition and its potential impact on the industry.
In a statement regarding the acquisition, David Wallace, Co-Founder and Managing Partner of Greenleaf Ventures, expressed enthusiasm about the alignment between the two companies. He stated, “This acquisition aligns perfectly with Aptiva Medical’s mission to build a leading, nationwide direct-to-patient CGM business. The VeraMed team has built an excellent foundation of patient care, and Aptiva Medical will ensure a seamless transition for every patient while continuing to raise the bar on service and efficiency.”
Enhancing Patient Care and Service
Aptiva Medical is recognized for its comprehensive approach to diabetes management, providing patients with essential services such as prescription coordination, insurance billing, and convenient home delivery of CGMs and diabetes testing supplies. The integration of VeraMed Health is anticipated to enhance these offerings further, ensuring that patients receive consistent and quality care throughout their management journey.
The acquisition also reflects a growing trend in the healthcare industry where companies are merging to create more robust networks that can provide better support to patients. By joining forces with VeraMed, Aptiva Medical is positioned to leverage synergies that can lead to improved patient outcomes and increased adherence to treatment plans.
As diabetes remains a critical public health issue, solutions that simplify management and ensure access to necessary resources are more important than ever. Aptiva Medical’s expansion through this acquisition is a proactive response to these ongoing challenges.
About the Companies Involved
Aptiva Medical, headquartered in Fort Lauderdale, Florida, is a national leader in the home delivery of continuous glucose monitors, diabetes testing supplies, and specialty transplant medications. The company’s commitment to end-to-end patient support positions it as a vital resource in diabetes management.
Greenleaf Ventures, also based in Fort Lauderdale, specializes in healthcare investments and has a proven track record of building and exiting companies with a combined enterprise value exceeding $500 million. Their focus on innovative healthcare solutions aligns with the overarching goal of improving patient care in a rapidly evolving landscape.
This acquisition not only represents a significant development for Aptiva Medical but also sets the stage for future advancements in diabetes care, reinforcing the importance of strategic partnerships in the healthcare sector. As the company moves forward, patients and stakeholders alike will be watching closely to see how these changes enhance the quality of care and service in the diabetes management arena.
